Loading…

Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy

One of the major barriers in utilizing prodrug nanocarriers for cancer therapy is the slow release of parent drug in tumors. Tumor cells generally display the higher oxidative level than normal cells, and also displayed the heterogeneity in terms of redox homeostasis level. We previously found that...

Full description

Saved in:
Bibliographic Details
Published in:Asian journal of pharmceutical sciences 2020-09, Vol.15 (5), p.637-645
Main Authors: Yang, Bin, Wei, Lin, Wang, Yuequan, Li, Na, Ji, Bin, Wang, Kaiyuan, Zhang, Xuanbo, Zhang, Shenwu, Zhou, Shuang, Yao, Xiaohui, Song, Hang, Wu, Yusheng, Zhang, Haotian, Kan, Qiming, Jin, Tao, Sun, Jin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the major barriers in utilizing prodrug nanocarriers for cancer therapy is the slow release of parent drug in tumors. Tumor cells generally display the higher oxidative level than normal cells, and also displayed the heterogeneity in terms of redox homeostasis level. We previously found that the disulfide bond-linkage demonstrates surprising oxidation-sensitivity to form the hydrophilic sulfoxide and sulphone groups. Herein, we develop oxidation-strengthened prodrug nanosystem loaded with pyropheophorbide a (PPa) to achieve light-activatable cascade drug release and enhance therapeutic efficacy. The disulfide bond-driven prodrug nanosystems not only respond to the redox-heterogeneity in tumor, but also respond to the exogenous oxidant (singlet oxygen) elicited by photosensitizers. Once the prodrug nanoparticles (NPs) are activated under irradiation, they would undergo an oxidative self-strengthened process, resulting in a facilitated drug cascade release. The IC50 value of the PPa@PTX-S-S NPs without irradiation was 2-fold higher than those of NPs plus irradiation. In vivo, the PPa@PTX prodrug NPs display prolonged systemic circulation and increased accumulation in tumor site. The PPa@PTX-S-S NPs showed much higher efficiency than free PTX or the PPa@PTX-C-C NPs to suppress the growth of 4T1 tumors. Therefore, this novel oxidation-strengthened disulfide-bridged prodrug-nanosystem has a great potential in the enhanced efficacy of cancer synergetic photochemotherapy. Firstly, the prodrug nanosystems containing disulfide bond could realize chemo-photodynamic therapy in response to the endogenous and endogenous ROS concentration, leading to an obvious cytotoxicity in cancer cells. Secondly, the PPa@PTX prodrug NPs display prolonged systemic circulation and increased accumulation in tumor site. Lastly, the in vivo antitumor efficiency demonstrated that the oxidation-strengthened PPa@PTX prodrug NPs efficiently inhibit the growth of 4T1 tumors. (A) The self-assembly process of disulfide bond-driven prodrug NPs; (B) Schematic illustration of prodrug NPs displayed light-activated fast drug release and chemo-photodynamic therapy. [Display omitted]
ISSN:1818-0876
2221-285X
DOI:10.1016/j.ajps.2019.09.001